A$7m Initial Public Offering
In November 2016, Neurotech International Limited completed a A$7m Initial Public Offering at A$0.20 per share and was admitted to the Australian Stock Exchange.
Neurotech is focused on the development and commercialisation of regulated medical solutions for diagnosis and treatment of neurological disorders. Its flagship device, Mente Autism, is an independently certified medical device that provides neurofeedback therapy to children on the autism spectrum at home.
Azure acted as the lead manager and financial adviser on two pre-IPO investment rounds for Neurotech in 2015 and 2016, and continued in this role to see the company through its IPO and most recent capital raising.